Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group.
Bateman RJ, et al.
N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.
N Engl J Med. 2023.
PMID: 37966285
Clinical Trial.
Across both trials, participants receiving gantenerumab had lower CSF levels of phosphorylated tau 181 and higher levels of Abeta42 than those receiving placebo; the accumulation of aggregated tau on PET was similar in the two groups. Amyloid-related imaging abnormalities with ed …
Across both trials, participants receiving gantenerumab had lower CSF levels of phosphorylated tau 181 and higher levels of Abeta42 than tho …